DATA FROM EXELIXIS CLINICAL TRIALS TO BE PRESENTED AT CONFERENCE
Exelixis has been notified by three of its clinical investigators that abstracts containing data from the company's ongoing Phase I clinical trials of XL647, XL999 and XL880 have been accepted for presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
The abstracts are: a Phase I dose-escalation and pharmacokinetic study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies; a Phase I dose-escalation and pharmacokinetic study of a novel spectrum selective kinase inhibitor, XL999, in patients with advanced solid malignancies; and a Phase I study of a novel spectrum selective kinase inhibitor, XL880, administered orally in patients with advanced solid malignancies.